Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Press releases

March 16, 2023 | REGULATORY

Bulletin from the extraordinary general meeting in Immunovia AB

Read press release
March 1, 2023 | REGULATORY

Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

Read press release
February 23, 2023 | REGULATORY

Immunovia Publishes Full Year Report for 2022

Read press release
February 20, 2023

Invitation to Immunovia’s Q4 presentation

Read press release
February 20, 2023 | REGULATORY

CONVENING NOTICE – EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (publ)

Read press release
February 20, 2023 | REGULATORY

Immunovia resolves on a rights issue of approximately SEK 202.2 million and postpones the publication of the quarterly report for the first quarter and the annual general meeting

Read press release
February 8, 2023

Consultation process with Swedish unions completed

Read press release
January 19, 2023

Immunovia announces updated financial calendar for financial year 2023

Read press release
January 19, 2023

Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test

Read press release
January 17, 2023

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Read press release
December 5, 2022

Immunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d test

Read press release
November 30, 2022

Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia’s IMMray PanCan-d test

Read press release
1 2 3 4 5 … 27
Home Press releases Page 3